Focus on current and emerging treatment options for glioma: A comprehensive review

Table 3 Supratentorial surgical treatment options for glioma, n (%)

Ref.	Study origin	Study design	Total number of patients	Supratotal resection sample	Male, %	Age atresection	Permanent neurological deficits	Progression-free survival	Overall survival
Gajjar et al[63], 1997	United States	Cohort study	142	48 (68/142)	61	7 median (0.17-19)	Not reported	70 ± 5 at 4 years	90 ± 3 at 4 years
Fisher et al[67], 2008	United States	Cohort study	278	19 (52/278)	58	9.1 ± 0.3	Not reported	55 ± 3 at 5 years	87 ± 2 at 5 years
Wisoff et al[125], 2010	United States	Prospective trial	518	64 (332/518)	54	7.9 median (0.6-20.5)	Not reported	78 ± 2 at 8 years	96 ± 0.9 at 8 years
Yordanova et al[93], 2011	France	Case series	15	100.00	53.3	36.4 (24-59)	2, 13.3	73.3 at 38 months	100 at study end
Youland et al[11], 2013	United States	Retrospective cohort	351	67 (235/351)	55	10.9 (0.05-19.6)	Not reported	75.8 at 5 years	94.9 at 5 years
Lima et al[126], 2015	France	Case series	21	19.0 (4/21)	28.57	35 (18-57)	0, 0	100 at study end	100 at study end
Duffau et al[127], 2016	France	Cohort study	16	100.00	43.75	41.3 (26-63)	0, 0	50 relapse rate (avg 70 months)	100 at study end
Lima et al[92], 2017	France	Two-center prospective study	19	26.3 (5/19)	42.1	31.2 (19-51)	0, 0	100 at study end	100 at study end
Rossi et al[86], 2019	Italy	Case series	449	32 (145/449)	53.1	37.9 (median 36.5)	1, 0.69 (SupTR group)	Not reported	Not reported
Ng et al[128], 2020	France	Case series	74	28 (21/74)	41.89	35.7 (18-66)	0, 0	Not reported	100 at 5 years
Ng et al[129], 2020	France	Case series	47	26 (12/47)	34.04	39.2 ± 11.3	0, 0	Not reported	100 at study end
Goel et al[130], 2021	India	Cohort study	74	34 (25/74)	62.16	33 (21-55)	0, 0	98.7 at 2 years	100 at study end
Rossi et al[94], 2021	Italy	Case series	319	35 (110/319)	61.1	38.9 (18-75)	6, 1.9	94 at 92 months (SupTR group)	100 at 80 months (SupTR group)
Ius et al[131], 2022	United States, Canada, France, and Italy	Four center retrospective review	267	9 (24/267)	41.9	39.2 (18-71)	8, 3.1	Not reported	100 at 100 months (SupTR)